Skip to content

A study on the effect of SNR16 intake during the follicular phase on skin condition

A study on the effect of SNR16 intake during the follicular phase on skin condition -A Randomized, Open-Label, No Intake Controlled, Crossover Study- - A study on the effect of SNR16 intake during the follicular phase on skin condition -A Randomized, Open-Label, No Intake Controlled, Crossover Study-

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049199
Enrollment
100
Registered
2023-10-24
Start date
2022-10-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Oral ingestion of SNR16 (1 pack per day for 6 days during follicular phase) No intervention

Sponsors

TES Holdings CO., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: [1] Those who experience changes in skin condition according to their menstrual cycle. [2] Those with regular menstrual cycles (26-35 days). [3] Those who are able to consume the test foods, participate in necessary examinations, and answer questionnaires according to the schedule instructed by the researcher.

Exclusion criteria

Exclusion criteria: [1] Those who may show severe allergic symptoms to foods (especially soybeans, gelatin, oranges). [2] Habitual users of health foods or supplements containing vitamin D within 1 month of study entry. [3] Those who have undergone cosmetic procedures (cosmetic surgery, collagen injection, laser, hair removal, etc.) within 6 months of the start of the examination. [4] Those who are exposed to excessive ultraviolet rays, such as those who work outdoors for long hours on a daily basis. [5] Those whose BMI deviates from 18.5 to 25. [6] Pregnant or lactating mothers, or those who wish to become pregnant during the study period. [7] Those who have some kind of chronic disease and are receiving drug treatment. [8] Persons who are judged to be inappropriate as subjects by the principal investigator and the principal investigator.

Design outcomes

Primary

MeasureTime frame
Perception of skin condition

Secondary

MeasureTime frame
Skin Moisture Content Skin Moisture Evaporation Skin smoothness Skin roughness Scaling Wrinkles

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings CO., Ltd. Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp03-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026